Nasal polyposis
Drug research and approvals for nasal polyposis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 42 studies of nasal polyposis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 13 drug trials for it since 2013.
- Recruiting worldwide: 42
- Trials authorized in Canada: 13
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 42 recruiting on ClinicalTrials.gov ↗
- Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis With Nasal PolypsNCT07860411 · Not reported · Harran University · starts Mar 15, 2026
- Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).NCT07814924 · Phase 4 · Instituto de Investigación Marqués de Valdecilla · starts Dec 31, 2024
- A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis…NCT07782970 · Phase 3 · GlaxoSmithKline · starts Sep 28, 2026
- A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With…NCT07782957 · Phase 3 · GlaxoSmithKline · starts Sep 3, 2026
- Triamcinolone Nanocapsules After Endoscopic Nasal SurgeryNCT07714525 · Phase 2 · Deraya University · starts May 1, 2026
- Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese…NCT07701967 · Phase 4 · GlaxoSmithKline · starts Jul 15, 2026
- Cognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell TrainingNCT07681973 · Not applicable · The Cleveland Clinic · starts Dec 9, 2025
- Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and…NCT07633158 · Not reported · AstraZeneca · starts Jun 10, 2026
- A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With TezepelumabNCT07520162 · Phase 3 · AstraZeneca · starts Apr 24, 2026
The 10 newest of 13; search them all in Canada trials
| Feb 24, 2026 | A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic…Itepekimab (SAR440340) | Sanofi-Aventis Canada Inc | Closed |
| Dec 5, 2024 | A randomized, double-blind, placebo-controlled, parallel-group, 52-week phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in…SAR440340 (itepekimab) | Sanofi-Aventis Canada Inc | Ongoing |
| Dec 5, 2024 | A randomized, double-blind, placebo-controlled, parallel-group, 52-week phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in…SAR440340 (itepekimab) | Sanofi-Aventis Canada Inc | Closed |
| Nov 6, 2024 | A multicentre, single-arm, phase 3b study to assess changes in symptoms in adult participants with chronic rhinosinusitis with nasal polyposis initiating…Tezepelumab | AstraZeneca Pharmaceuticals | Ongoing |
| Apr 25, 2024 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of lebrikizumab/LY3650150 in…Lebrikizumab (LY3650150) | Eli Lilly | Ongoing |
| Nov 13, 2020 | A multicentre, randomised, double-blind, parallel-group, placebo-controlled phase 3 efficacy and safety study of tezepelumab in participants with severe…Tezepelumab (MEDI9929/AMG 157) | AstraZeneca Pharmaceuticals | Ongoing |
| Jun 30, 2020 | A multicentre, double-blind, parallel-group, placebo-controlled phase 3 efficacy and safety study of benralizumab for the prevention of recurrence of nasal…Benralizumab (MEDI-563) | AstraZeneca Pharmaceuticals | Pending |
| Dec 5, 2018 | A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SOC) for assessment of the…Fevipiprant (QAW039) | Novartis Pharmaceuticals | Ongoing |
| Mar 7, 2018 | Open-label extension study of omalizumab in patients with chronic rhinosinusitis with nasal polypsXolair | Roche | Closed |
| Dec 27, 2017 | A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 efficacy and safety study of benralizumab in patients with severe nasal…MEDI-563 | AstraZeneca Pharmaceuticals | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA